Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year
ALBANY, N.Y., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia),…
Dansy Labs Announces USD 120 Million Major Strategic Asset Buyout and Patents in Hong Kong and Sweden
In a landmark move aimed at significantly enhancing its research and development…
Jubilant Biosys Limited Seals Deal with Pierre Fabre SA
To acquire R&D center at Saint-Julien-en-Genevois, France To add Drug Discovery &…
TraceLink Recognized on Fast Company’s Next Big Things in Tech List
The annual list honors groundbreaking advancements redefining the way we work and…
BTL’s EMSCULPT NEO Used in Astronaut Training in Hungary for International Space Mission
PRAGUE, Oct. 20, 2025 /PRNewswire/ -- BTL, a global leader in medical technologies,…
Medkart Launches India's First Tool to Find Substitute Medicine and Compare Prices, Transforming Access to Affordable Healthcare
In a significant stride towards affordable healthcare, Medkart Pharmacy has unveiled India's…
Florricks Lifecare Expands Global Footprint with USD 95 Million Investment in Europe and Hong Kong
Florricks Lifecare Private Limited, a leading research-driven global pharmaceutical company renowned for…
Manipal Hospital Sarjapur Road Empowers Fitness Enthusiasts with CPR Skills and First-Aid Workshop
BENGALURU, India, Oct. 14, 2025 /PRNewswire/ -- With the growing emphasis on…
Improving Public Health in the Global South by Leveraging Innovative Smoke-free Alternatives, focus at Technovation’25
NEW DELHI, Oct. 14, 2025 /PRNewswire/ -- Philip Morris International (PMI) recently hosted…
Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…